SAFE - Bond financing agreement in a minimum amount of €850,000 to support the Group’s turnaround strategy
11 Marzo 2024 - 1:00AM
SAFE - Bond financing agreement in a minimum amount of €850,000 to
support the Group’s turnaround strategy
Bond financing agreement in a minimum
amount of €850,000 to support the Group’s
turnaround strategy
Eragny-sur-Oise –
France – March 11, 2024, 8.00 a.m. Safe SA
(the “Company”) announces that it has arranged
flexible bond financing with the Global Corporate Finance
Opportunities 20 (GCFO 20) fund, a member of the Alpha Blue
Ocean (ABO) group, through the issuance of warrants giving access
to bonds convertible or exchangeable into new and/or existing
shares with warrants attached in a minimum net amount of
approximately €850,000. At a time when the Group is under
observation, this financing will facilitate the implementation of
the restructuring plan initiated by the new management team.
Under the terms of a convertible or exchangeable
bond financing agreement signed on March 14, 2023 between Safe SA
and the GCFO 20 fund, the GCFO 20 fund has undertaken to
finance the Group’s observation period in a minimum net amount of
approximately €850,000.
ABO Participation undertakes to ensure that this
financing is carried out through the drawdown, by Safe SA, of three
tranches (the “Authorized Tranches”) of bonds convertible or
exchangeable into new and/or existing shares (the “OCEANE bonds”)
with warrants attached (the “warrants”) to be subscribed for by
GCFO 20 under the terms of the Subscription Agreement
(excluding any commitment fee due), as follows:
Authorized Tranche |
Number of OCEANE bonds issued |
Nominal amount (in euros) |
Subscription price (97% of the nominal amount) (in
euros) |
Drawdown date of the relevant Authorized
Tranche |
1 |
310 |
310,000 |
300,700 |
Within 5 trading days of delivery of the order issued by the
juge-commissaire (official receiver) |
2 |
310 |
310,000 |
300,700 |
After a period of 20 trading days following the issue of the
previous Authorized Tranche |
3 |
260 |
260,000 |
252,200 |
After a period of 20 trading days following the issue of the
previous Authorized Tranche |
Total |
880 |
880,000 |
853,600 |
|
Within this framework, ABO Participation
declares in advance that it waives all the conditions precedent
provided for in the Subscription Agreement in connection with the
drawing down of the Authorized Tranches, it being specified that
this waiver applies only to the Authorized Tranches, to the
exclusion of any other tranche issued under the Subscription
Agreement.
ABO Participation further undertakes not to
convert the OCEANE bonds issued under the Authorized Tranches into
new shares until the Pontoise Commercial Court adopts a
continuation plan for Safe SA at the end of the observation period
and, if the observation period has not ended by that date, not
before June 30, 2024.
As subscription for the Authorized Tranches by
GCFO 20 has the characteristics of a new contribution granted
with a view to ensuring the continuation of the business for the
duration of the proceedings, it is subject to the authorization of
the juge-commissaire (official receiver) (in accordance with
paragraph 2 of Article L. 622-17 III 4° of the French
Commercial Code and must benefit from the preferential right
provided for in III 2° of that Article. Consequently, the first
Authorized Tranche will be drawn down within 5 trading days of the
order being issued by the official receiver, in accordance with the
above-mentioned table, and must be followed by the issuance of a
press release from Safe SA announcing the schedule for drawing down
the Authorized Tranches in accordance with the terms of the
Subscription Agreement.
The Company undertakes to keep an up-to-date
table on its website showing the number of OCEANE bonds and shares
outstanding.
Financial calendar:2023 annual
results and 2023 annual financial report, April 30
About Safe Group
Safe Group is a French medical technology group
that brings together Safe Orthopaedics, a pioneer in ready-to-use
technologies for spine pathologies, and Safe Medical (formerly LCI
Medical), a medical device subcontractor for orthopedic surgeries.
The group employs approximately 100 people.Safe Orthopaedics
develops and manufactures kits combining sterile implants and
ready-to-use instruments, available at any time to the surgeon.
These technologies are part of a minimally invasive approach aimed
at reducing the risks of contamination and infection, in the
interest of the patient and with a positive impact on
hospitalization times and costs. Protected by 15 patent families,
SteriSpineTM kits are CE marked and FDA approved. Safe Orthopaedics
has subsidiaries in the United Kingdom, Germany, the United
States.For more information: www.safeorthopaedics.com
Safe Medical produces implantable medical
devices and ready-to-use instruments. It has an innovation center
and two production sites in France and in Tunisia, offering
numerous industrial services: industrialization, machining,
finishing and sterile packaging.For more information:
www.safemedical.fr
Contacts
SAFE
GROUP AELYON
ADVISORSinvestors@safeorthopaedics.com safe@aelyonadvisors.fr
SAFE (EU:ALSAF)
Gráfica de Acción Histórica
De Nov 2024 a Dic 2024
SAFE (EU:ALSAF)
Gráfica de Acción Histórica
De Dic 2023 a Dic 2024